To elucidate the clinical significance of KAT2A in DLBCL, we knocked down KAT2A in two DLBCL cell lines (OCI-LY1 and U2932), resulting in stable KAT2A KD cell lines (Fig. 7A-B), of which shKAT2A#3 exhibited the highest efficacy. Here, KAT2A is linked to diffuse large B-cell lymphoma.